International Journal of Molecular Sciences (Jul 2020)
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
- Yoshio Sumida,
- Masashi Yoneda,
- Hidenori Toyoda,
- Satoshi Yasuda,
- Toshifumi Tada,
- Hideki Hayashi,
- Yoichi Nishigaki,
- Yusuke Suzuki,
- Takafumi Naiki,
- Asahiro Morishita,
- Hiroshi Tobita,
- Shuichi Sato,
- Naoto Kawabe,
- Shinya Fukunishi,
- Tadashi Ikegami,
- Takaomi Kessoku,
- Yuji Ogawa,
- Yasushi Honda,
- Takashi Nakahara,
- Kensuke Munekage,
- Tsunehiro Ochi,
- Koji Sawada,
- Atsushi Takahashi,
- Taeang Arai,
- Tomomi Kogiso,
- Satoshi Kimoto,
- Kengo Tomita,
- Kazuo Notsumata,
- Michihiro Nonaka,
- Kazuhito Kawata,
- Taro Takami,
- Takashi Kumada,
- Eiichi Tomita,
- Takeshi Okanoue,
- Atsushi Nakajima,
- Japan Study Group of NAFLD (JSG-NAFLD)
Affiliations
- Yoshio Sumida
- Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan
- Masashi Yoneda
- Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan
- Hidenori Toyoda
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan
- Satoshi Yasuda
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan
- Toshifumi Tada
- Department of Hepatology, Himeji Redcross Hospital, Himeji, Hyogo 670-8540, Japan
- Hideki Hayashi
- Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
- Yoichi Nishigaki
- Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
- Yusuke Suzuki
- Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
- Takafumi Naiki
- Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
- Asahiro Morishita
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761-0793, Japan
- Hiroshi Tobita
- Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Izumo, Shimane 693-8501, Japan
- Shuichi Sato
- Department of Internal Medicine, Izumo City General Medical Center, Izumo, Shimane 691-0003, Japan
- Naoto Kawabe
- Department of Liver, Biliary Tract and Pancreas Diseases, Fujita Health University School of Medicine, Aichi 470-1192, Japan
- Shinya Fukunishi
- Premier Development Research of Medicine, Osaka Medical College, Osaka 569-8686, Japan
- Tadashi Ikegami
- Department of Gastroenterology, Tokyo Medical University Ibaraki Medical Center, Ibaraki 300-0395, Japan
- Takaomi Kessoku
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan
- Yuji Ogawa
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan
- Yasushi Honda
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan
- Takashi Nakahara
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan
- Kensuke Munekage
- Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi 780-8505, Japan
- Tsunehiro Ochi
- Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi 780-8505, Japan
- Koji Sawada
- Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical University, Asahikawa 078-8510, Japan
- Atsushi Takahashi
- Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan
- Taeang Arai
- Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo 113-8602, Japan
- Tomomi Kogiso
- Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo 162-8266, Japan
- Satoshi Kimoto
- Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan
- Kengo Tomita
- Department of Internal Medicine, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan
- Kazuo Notsumata
- Department of General Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui 918-8503, Japan
- Michihiro Nonaka
- Department of Gastroenterology and Hepatology, JA Hiroshima General Hospital, Hiroshima 738-8503, Japan
- Kazuhito Kawata
- Hepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan
- Taro Takami
- Department of Gastroenterology and Hepatology, Yamaguchi University, Ube, Yamaguchi 755-8505, Japan
- Takashi Kumada
- Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Gifu 503-8502, Japan
- Eiichi Tomita
- Department of Gastroenterology, Gifu Municipal Hospital, Gifu 500-8513, Japan
- Takeshi Okanoue
- Hepatology Center, Saiseikai Suita Hospital, Suita, Osaka 564-0013, Japan
- Atsushi Nakajima
- Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yohokama, Kanagawa 236-0004, Japan
- Japan Study Group of NAFLD (JSG-NAFLD)
- DOI
- https://doi.org/10.3390/ijms21144939
- Journal volume & issue
-
Vol. 21,
no. 14
p. 4939
Abstract
Type 2 diabetes (T2D) is associated with diabetic nephropathy as well as nonalcoholic steatohepatitis (NASH), which can be called “diabetic hepatopathy or diabetic liver disease”. NASH, a severe form of nonalcoholic fatty disease (NAFLD), can sometimes progress to cirrhosis, hepatocellular carcinoma and hepatic failure. T2D patients are at higher risk for liver-related mortality compared with the nondiabetic population. NAFLD is closely associated with chronic kidney disease (CKD) or diabetic nephropathy according to cross-sectional and longitudinal studies. Simultaneous kidney liver transplantation (SKLT) is dramatically increasing in the United States, because NASH-related cirrhosis often complicates end-stage renal disease. Growing evidence suggests that NAFLD and CKD share common pathogenetic mechanisms and potential therapeutic targets. Glucagon-like peptide 1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are expected to ameliorate NASH and diabetic nephropathy/CKD. There are no approved therapies for NASH, but a variety of drug pipelines are now under development. Several agents of them can also ameliorate diabetic nephropathy/CKD, including peroxisome proliferator-activated receptors agonists, apoptosis signaling kinase 1 inhibitor, nuclear factor-erythroid-2-related factor 2 activator, C-C chemokine receptor types 2/5 antagonist and nonsteroidal mineral corticoid receptor antagonist. This review focuses on common drug pipelines in the treatment of diabetic nephropathy and hepatopathy.
Keywords
- diabetic nephropathy
- diabetic hepatopathy
- chronic kidney disease
- glucagon-like peptide 1
- peroxisome proliferator-activated receptor
- sodium–glucose cotransporter 2
